-
Je něco špatně v tomto záznamu ?
An in vivo study of intravitreal ranibizumab following subretinal inoculation of RB cells in rabbits' eyes
AA. Azimah Nor, SJ. Toh Diana, TK. Fathlun Ain Tengku, S. Sarina, Shamel Khairy ST., Y. Azhany, O. Nor Hayati, AT. Liza-Sharmini
Jazyk angličtina Země Česko
- MeSH
- inhibitory angiogeneze farmakologie MeSH
- injekce intravitreální MeSH
- králíci MeSH
- modely nemocí na zvířatech MeSH
- nádory sítnice chemicky indukované farmakoterapie MeSH
- ranibizumab * terapeutické užití MeSH
- retinoblastom * chemicky indukované farmakoterapie MeSH
- vaskulární endoteliální růstový faktor A MeSH
- zvířata MeSH
- Check Tag
- králíci MeSH
- zvířata MeSH
Aim: This study aimed to determine the effects of a single intravitreal ranibizumab injection in rabbits induced with retinoblastoma (RB). Material and Methods: RB was induced in six New Zealand white rabbits by subretinal injection of a cultured WERI-RBb-1 cell line into the right eye. After six weeks, Group A (n = 3) was given intravitreal ranibizumab injection (0.3mg in 0.03ml) and Group B (n = 3) was the control. Baseline and serial clinical examinations were performed on days 1, 3, 6, 12, 15, 18 and 21. The right eyes were enucleated for both groups on day 21 for histopathological examination. Results: The rabbits in both groups developed intraocular lesions which was detectable clinically at one-week post-tumor inoculation. The tumor grew slowly without spontaneous regression. After the animals in Group A were given an intravitreal ranibizumab injection, regression of the tumor was detected clinically, while the tumor in Group B continued to grow slowly. Histopathological findings confirmed the presence of a tumor that closely resembled features of poorly differentiated human RB cells. At the end of 21 days, the size of the tumor was larger in Group B in comparison to Group A. However, the treated group also developed a focal area of retinal hyperplasia. There was no significant side effect of ranibizumab injection except temporary high intraocular pressure immediately post-injection, which was relieved after paracentesis. Conclusions: Intravitreal ranibizumab is a potential treatment for RB. It is an effective therapy with a tolerable safety profile in this animal experimental study.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22015887
- 003
- CZ-PrNML
- 005
- 20220729164320.0
- 007
- ta
- 008
- 220704s2022 xr cad f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.31348/2022/13 $2 doi
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Azimah Nor, A. A. $u Department of Ophthalmology and Visual Science, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan $u Department of Ophthalmology, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Selangor Branch, 47000 Jalan Hospital, Sungai Buloh, Selangor
- 245 13
- $a An in vivo study of intravitreal ranibizumab following subretinal inoculation of RB cells in rabbits' eyes / $c AA. Azimah Nor, SJ. Toh Diana, TK. Fathlun Ain Tengku, S. Sarina, Shamel Khairy ST., Y. Azhany, O. Nor Hayati, AT. Liza-Sharmini
- 520 9_
- $a Aim: This study aimed to determine the effects of a single intravitreal ranibizumab injection in rabbits induced with retinoblastoma (RB). Material and Methods: RB was induced in six New Zealand white rabbits by subretinal injection of a cultured WERI-RBb-1 cell line into the right eye. After six weeks, Group A (n = 3) was given intravitreal ranibizumab injection (0.3mg in 0.03ml) and Group B (n = 3) was the control. Baseline and serial clinical examinations were performed on days 1, 3, 6, 12, 15, 18 and 21. The right eyes were enucleated for both groups on day 21 for histopathological examination. Results: The rabbits in both groups developed intraocular lesions which was detectable clinically at one-week post-tumor inoculation. The tumor grew slowly without spontaneous regression. After the animals in Group A were given an intravitreal ranibizumab injection, regression of the tumor was detected clinically, while the tumor in Group B continued to grow slowly. Histopathological findings confirmed the presence of a tumor that closely resembled features of poorly differentiated human RB cells. At the end of 21 days, the size of the tumor was larger in Group B in comparison to Group A. However, the treated group also developed a focal area of retinal hyperplasia. There was no significant side effect of ranibizumab injection except temporary high intraocular pressure immediately post-injection, which was relieved after paracentesis. Conclusions: Intravitreal ranibizumab is a potential treatment for RB. It is an effective therapy with a tolerable safety profile in this animal experimental study.
- 650 07
- $a inhibitory angiogeneze $x farmakologie $7 D020533 $2 czmesh
- 650 07
- $a zvířata $7 D000818 $2 czmesh
- 650 07
- $a injekce intravitreální $7 D058449 $2 czmesh
- 650 07
- $a králíci $7 D011817 $2 czmesh
- 650 17
- $a ranibizumab $x terapeutické užití $7 D000069579 $2 czmesh
- 650 07
- $a nádory sítnice $x chemicky indukované $x farmakoterapie $7 D019572 $2 czmesh
- 650 17
- $a retinoblastom $x chemicky indukované $x farmakoterapie $7 D012175 $2 czmesh
- 650 07
- $a vaskulární endoteliální růstový faktor A $7 D042461 $2 czmesh
- 650 _7
- $a modely nemocí na zvířatech $7 D004195 $2 czmesh
- 700 1_
- $a Toh, Diana S. J. $u Department of Ophthalmology and Visual Science, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan
- 700 1_
- $a Tengku Ain Fathlun, T. K. $u Department of Ophthalmology, Faculty of Medicine, Universiti Malaya, Lembah Pantai, 59090 Kuala Lumpur, Wilayah Persekutuan $u University Malaya Eye Research Centre, Faculty of Medicine, Universiti Malaya, Lembah Pantai, 59090 Kuala Lumpur, Wilayah Persekutuan
- 700 1_
- $a Sarina, S. $u Human Genome Centre, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan
- 700 1_
- $a Khairy, Shamel, S. T. $u Department of Ophthalmology and Visual Science, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan
- 700 1_
- $a Azhany, Y. $u Department of Ophthalmology and Visual Science, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan
- 700 1_
- $a Hayati Nor, O. $u Department of Pathology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan
- 700 1_
- $a Sharmini, Liza, A. T. $u Department of Ophthalmology and Visual Science, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan
- 773 0_
- $w MED00010980 $t Česká a slovenská oftalmologie $x 1211-9059 $g Roč. 78, č. 3 (2022), s. 112-120
- 856 41
- $u https://www.prolekare.cz/casopisy/ceska-slovenska-oftalmologie/2022-3-3/an-in-vivo-study-of-intravitreal-ranibizumab-following-subretinal-inoculation-of-rb-cells-in-rabbits-eyes-131012 $y plný text volně dostupný
- 910 __
- $a ABA008 $b A 202 $c 639 $y p $z 0
- 990 __
- $a 20220704 $b ABA008
- 991 __
- $a 20220729164312 $b ABA008
- 999 __
- $a ok $b bmc $g 1813541 $s 1167123
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 78 $c 3 $d 112-120 $i 1211-9059 $m Česká a slovenská oftalmologie $x MED00010980 $y 131012
- LZP __
- $c NLK109 $d 20220729 $b NLK111 $a Meditorial-20220704
